newsfilter
← Latest News
GlobeNewswire·

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

  • Pyxis Oncology announced updated Phase 1 monotherapy results for micvotabart pelidotin (MICVO) in 2L+ R/M HNSCC as of the October 14, 2026 data cutoff.
  • Updated efficacy data showed a 39% confirmed objective response rate (cORR), 94% disease control rate, median progression-free survival of 6.7 months, 12-month overall survival probability of 81%, & median duration of response of 9.2 months.
  • Clinical activity was consistent across HPV status subgroups (41% cORR for HPV+ & 38% for HPV-unrelated) & prior-treatment groups, including patients with prior EGFR inhibitors.
  • Safety profile remained manageable with no new Grade 3 peripheral neuropathy cases; 83% of existing Grade 3 cases resolved to Grade 1 or better.
  • A new analysis indicated MICVO increased median progression-free survival by 50% compared to the most recent prior therapy.
  • Patients receiving a capped dose demonstrated better outcomes than those dosed above the cap, with 0% Grade 3 peripheral neuropathy in the capped group versus 67% in the uncapped group.
  • The company plans to advance MICVO into the global Phase 3 Headliner SM trial, expected to initiate in mid-2027.
  • Results will be presented via late-breaking oral presentation by Dr. Faye Johnson at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026.
  • Pyxis Oncology will host a live webcast on November 19, 2026, at 7:00 a.m. EST to discuss the findings following the presentation.
  • MICVO holds Fast Track Designation from the FDA for R/M HNSCC patients who progressed after platinum chemotherapy & anti-PD-(L)1 therapy.
Company
Pyxis Oncology
Keywords
Nasdaq:PYXS, Pyxis Oncology